[HTML][HTML] A levodopa dry powder inhaler for the treatment of Parkinson's disease patients in off periods

M Luinstra, F Grasmeijer, P Hagedoorn… - European Journal of …, 2015 - Elsevier
Adequate treatment of Parkinson's patients in off periods with orally administered levodopa
is hindered by a poor bioavailability and a slow onset of action. Hence, there is a need for a …

Bevacizumab for intravitreal injection: impact of sub-visible particles on the shelf-life of repackaged bevacizumab

M Crul, A Zandvliet, JR Moes, T Veenbaas… - Journal of Ocular …, 2019 - liebertpub.com
Abstract Purpose: Bevacizumab (Avastin) is a humanized monoclonal antibody approved by
the European Medicines Agency for the intravenous treatment of cancer. However, it is often …

Ready-to-use parenteral amiodarone: a feasibility study towards a long-term stable product formulation

MS Jacobs, M Luinstra, JR Moes, TCY Chan… - European Journal of …, 2017 - ejhp.bmj.com
Objectives To determine the feasibility of preparing a long-term stable ready-to-use
parenteral amiodarone formulation using cyclodextrins as dissolution enhancer. Methods A …

[CITATION][C] Kwalificatie van de zero-residual syringe (Zeringe) als verpakkingsmateriaal voor bevacizumab als intravitreale injectie

MS Jacobs, W Hemminga, H Woerdenbag… - Pharmaceutisch …, 2016 - research.rug.nl
Kwalificatie van de zero-residual syringe (Zeringe) als verpakkingsmateriaal voor
bevacizumab als intravitreale injectie — the University of Groningen research portal Skip to …

[CITATION][C] Zero-residual syringe als verpakkingsmateriaal voor bevacizumab als intravitreale injectie-Antwoord van de auteurs

MS Jacobs, WL Hemminga… - Pharmaceutisch …, 2017 - research.rug.nl
Zero residual syringe as a packaging material for bevacizumab and intravitreal injection -
Authors' reply — the University of Groningen research portal Skip to main navigation Skip to …